UNITED THERAPEUTICS Corp UTHR
- Employees
- 1,400
- Headquarters
- Silver Spring, MD
- CEO
- Martine A. Rothblatt
- Next results
- around Feb 24, 2027
Where each dollar of revenue went, FY2025
Revenue of $3.2B through the costs to a net profit of $1.3B · income statement of the 10-K
UTHR among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
7 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +25.4% ($279.3M to $350.2M) vs revenue +10.6% ($2.9B to $3.2B), +14.8 pts apart
-
Cash from operations $1.6B vs net income $1.3B (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +16.0% ($157.9M to $183.1M) vs revenue +10.6% ($2.9B to $3.2B), +5.3 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No longer listed: F-2 United Therapeutics, a public benefit corporation. Same as last year: Revenue Deductions — Accounting for Rebates; Our Audit
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
7 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Investing in our securities involves uncertainty and risk due to a variety of factors. You should carefully consider each of the following risks and all of the other information contained in this Report and in other documents that we file with, or furnish to, the SEC before making any investment decision with respect to our securities.…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
In April 2025, the Trump administration announced a reduction in force at the U.S. Department of Health and Human Services, including layoffs at the FDA. These and other efforts to reduce the size of the FDA or its funding, combined with changes in FDA leadership, have begun to result in slower FDA response times and/or longer review…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
More recently, the One Big Beautiful Bill Act, which was enacted in July 2025, significantly reduced funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of our commercial products. The…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.9B | $2.3B | $2.9B | $3.2B |
| Net income | $727.3M | $984.8M | $1.2B | $1.3B |
| Operating cash flow | $802.5M | $978.0M | $1.3B | $1.6B |
| Free cash flow | $663.7M | $747.6M | $1.1B | $1.0B |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$3.2B ▲ 10.6% in FY2025$1.3B ▲ 11.7% in FY2025$1.0B ▼ 3.7% in FY2025
Recent filings
6 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 9, 2026CHRISTOPHER PATUSKY (Director) gave notice of a planned sale of 1,210 shares worth about $702K Form 144, approximate sale date Nov 9, 2026
-
Planned saleNov 5, 2026PAUL MAHON (Officer) gave notice of a planned sale of 8,300 shares worth about $5.0M Form 144, approximate sale date Nov 5, 2026, under a 10b5-1 plan adopted Aug 11, 2025
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
Planned saleNov 2, 2026MARTINE ROTHBLATT (Director, Officer) gave notice of a planned sale of 119,410 shares worth about $71.5M Form 144, approximate sale date Nov 2, 2026, under a 10b5-1 plan adopted Nov 21, 2025
About the company
UNITED THERAPEUTICS Corp, Silver Spring, MD · from the 10-K filed Feb 25, 2026
Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.
- Headquarters
- Silver Spring, MD
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had approximately 1,400 employees working across our 15 locations worldwide" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UTHR/export.csv") into a cell.